Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Angiogenesis

Angiogenesis

Products for  Angiogenesis

  1. Cat.No. Product Name Information
  2. GC61520 Cilengitide TFA

    EMD 121974 TFA

     Cilengitide is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50 values of 4 nM and 79 nM, respectively. Cilengitide TFA Chemical Structure
  3. GC45880 Cimetidine-d3 An internal standard for the quantification of cimetidine Cimetidine-d3 Chemical Structure
  4. GC13439 CNX-774 BTK inhibitor, orally active, irreversible and selective CNX-774 Chemical Structure
  5. GC17631 Combretastatin A4

    CA4, Combretastatin A4, CRC 8709

     tubulin polymerization inhibitor Combretastatin A4 Chemical Structure
  6. GC74401 cRGDfK-thioacetyl ester TFA cRGDfK-thioacetyl ester TFA is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging. cRGDfK-thioacetyl ester TFA Chemical Structure
  7. GN10535 Cucurbitacin B

    Cuc B, NSC 49451, NSC 144154

     Cucurbitacin B Chemical Structure
  8. GC13050 CWHM-12 An inhibitor of αV integrins CWHM-12 Chemical Structure
  9. GC17610 Cyclo (-RGDfK)

    Cyclo(-Arg-Gly-Asp-D-Phe-Lys)

     An inhibitor of αvβ3 integrin Cyclo (-RGDfK) Chemical Structure
  10. GC60117 Cyclo(-RGDfK) TFA Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface. Cyclo(-RGDfK) TFA Chemical Structure
  11. GC68921 Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA

    Cyclo(RGDfC) TFA

    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA is a cyclic RGD peptide with high affinity for αvβ3 integrin, which can disrupt cell adhesion. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits the expression of pluripotency genes in embryonic stem cells (ESC), and suppresses the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used for tumor-related research.

     Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA Chemical Structure
  12. GC34141 Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an inhibitor of integrin αvβ3, with antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Chemical Structure
  13. GC30111 Cyclo(RADfK) Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis. Cyclo(RADfK) Chemical Structure
  14. GC13923 Cyclo(RGDyK) trifluoroacetate Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with IC50 of 20 nM. Cyclo(RGDyK) trifluoroacetate Chemical Structure
  15. GC47163 D-2-Aminoglutarimide (hydrochloride) A synthetic intermediate D-2-Aminoglutarimide (hydrochloride) Chemical Structure
  16. GC43514 D-myo-Inositol-1,3,4,5,6-pentaphosphate (ammonium salt)

    Ins(1,3,4,5,6)P5, 1,3,4,5,6IP5 (sodium salt)

     Inositol-1,3,4,5,6-pentaphosphate (Ins(1,3,4,5,6)P5) is one of the many inositol phosphate isomers that act as small, soluble second messengers in the transmission of cellular signals. D-myo-Inositol-1,3,4,5,6-pentaphosphate (ammonium salt) Chemical Structure
  17. GC43515 D-myo-Inositol-1,3,4,5,6-pentaphosphate (sodium salt)

    Ins(1,3,4,5,6)P5, 1,3,4,5,6IP5

     The phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway plays critical roles in cell growth and proliferation making it an attractive target for anticancer agents. D-myo-Inositol-1,3,4,5,6-pentaphosphate (sodium salt) Chemical Structure
  18. GC16647 Daprodustat(GSK1278863)

    GSK1278863

     Daprodustat(GSK1278863) (GSK1278863) is an orally active hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor being developed for the treatment of anemia associated with chronic kidney disease. Daprodustat(GSK1278863) Chemical Structure
  19. GC31230 Dencichin (Dencichine) Dencichin is a non-protein amino acid originally extracted from Panax notoginseng, and can inhibit HIF-prolyl hydroxylase-2 (PHD-2) activity. Dencichin (Dencichine) Chemical Structure
  20. GC38767 Deoxyshikonin A natural products with anti-tumor activity Deoxyshikonin Chemical Structure
  21. GC32449 Desidustat

    P 1560, β-Zearalanol, β-Zearanol

     An inhibitor of HIF-PH Desidustat Chemical Structure
  22. GC47234 Diosmetin-d3

    Diosmetol-d3, Luteolin 4'-methyl ester-d3

     An internal standard for the quantification of diosmetin Diosmetin-d3 Chemical Structure
  23. GC45767 Dovitinib-d8 An internal standard for the quantification of dovitinib Dovitinib-d8 Chemical Structure
  24. GC19128 E7820

    ER68203-00

     E7820 is an angiogenesis inhibitor by suppressing integrin a2, a cell adhesion molecule expressed on endothelial cells. E7820 Chemical Structure
  25. GC18236 Echinomycin

    Antibiotic A 654I； NSC 13502； NSC 526417； Quinomycin A； SK 302B

     An inhibitor of HIF1mediated gene transcription Echinomycin Chemical Structure
  26. GC62182 Echistatin TFA Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin TFA Chemical Structure
  27. GC17236 Echistatin, α1 isoform Echistatin, α1 isoform, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin, α1 isoform Chemical Structure
  28. GC69041 Efalizumab

    Efalizumab is a targeted T-cell modulator, which is a humanized monoclonal antibody against the LFA-1 alpha subunit CD11a. Efalizumab can inhibit T-cell activation, skin T-cell trafficking and T-cell adhesion to keratinocytes, and can be used in research on plaque psoriasis.

     Efalizumab Chemical Structure
  29. GC70986 Egaptivon pegol sodium Egaptivon pegol sodium is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol sodium Chemical Structure
  30. GC33043 EL-102 EL-102 is a hypoxia-induced factor 1 (Hif1α) inhibitor. EL-102 induces apoptosis, inhibits tubulin polymerisation and shows activities against prostate cancer. EL-102 can be used for the research of cancer. EL-102 Chemical Structure
  31. GC64819 Elsubrutinib

    ABBV-105

     Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor。The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib Chemical Structure
  32. GC69057 EMD527040

    EMD527040 is a highly efficient and selective αvβ6 antagonist with anti-fibrotic activity. It can be used for research on liver cancer and liver fibrosis.

     EMD527040 Chemical Structure
  33. GC33634 Enarodustat (JTZ-951)

    JTZ-951

     Enarodustat (JTZ-951) is a potent and orally active hypoxia-inducible factor prolyl hydroxylase inhibitor, with an EC50 of 0.22 μM. Enarodustat (JTZ-951) Chemical Structure
  34. GC69067 Enlimomab

    BI-RR 0001; Anti-Human IL6 Recombinant Antibody

    Enlimomab (BI-RR 0001) is a mouse IgG2a monoclonal antibody targeting human ICAM-1, which can inhibit leukocyte adhesion to vascular endothelium, thereby reducing leukocyte extravasation and inflammatory tissue damage. Enlimomab has anti-inflammatory effects and can be used in stroke research.

     Enlimomab Chemical Structure
  35. GC60807 ENMD-1068 hydrochloride

    6-Amino-1-[4-(3-methyl-1-oxobutyl)-1-piperazinyl]-1-hexanone hydrochloride

     Selective protease-activated receptor 2 (PAR2) anatagonist ENMD-1068 hydrochloride Chemical Structure
  36. GC33170 ENMD-119 (ENMD 1198)

    IRC-110160

     ENMD-119 (ENMD 1198) (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity. ENMD-119 (ENMD 1198) is suitable for inhibiting HIF-1alpha and STAT3 in human HCC cells and leads to reduced tumor growth and vascularization. ENMD-119 (ENMD 1198) Chemical Structure
  37. GC47298 Epalrestat-d5 A neuropeptide with diverse biological activities Epalrestat-d5 Chemical Structure
  38. GC12447 Eptifibatide Acetate

    Glycoprotein (GP) IIb/IIIa inhibitor

     Eptifibatide Acetate Chemical Structure
  39. GC68283 Etrolizumab

    rhuMAb Beta7; RG7413; PRO145223

     Etrolizumab Chemical Structure
  40. GC47328 Everolimus-d4

    RAD001-d4; SDZ-RAD-d4

     An internal standard for the quantification of everolimus Everolimus-d4 Chemical Structure
  41. GC34062 Evobrutinib (M2951) Evobrutinib, as an orally, highly selective, covalent Bruton's tyrosine kinase inhibitor, was well‐tolerated and effective. Evobrutinib (M2951) Chemical Structure
  42. GC16638 FG2216

    IOX3, YM-311

     HIF-prolyl hydroxylase inhibitor FG2216 Chemical Structure
  43. GC14804 Firategrast Firategrast Chemical Structure
  44. GC32562 Fradafiban (BIBU-52) Fradafiban (BIBU-52) is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. Fradafiban (BIBU-52) Chemical Structure
  45. GC70223 Fradafiban hydrochloride Fradafiban (BIBU-52) hydrochloride is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. Fradafiban hydrochloride Chemical Structure
  46. GC38044 Fraxinellone Fraxinellone Chemical Structure
  47. GC61501 FSLLRY-NH2 TFA FSLLRY-NH2 TFA is a protease-activated receptor 2 (PAR2) inhibitor. FSLLRY-NH2 TFA Chemical Structure
  48. GC43727 Ganglioside GD1a mixture (sodium salt)

    Ganglioside B1

    Ganglioside GD1a is a sialic acid-containing glycosphingolipid found in brain, erythrocytes, bone marrow, testis, spleen, and liver.

     Ganglioside GD1a mixture (sodium salt) Chemical Structure
  49. GC43732 Ganglioside GM3 Mixture (sodium salt)

    Hematoside, Monosialoganglioside GM1, Sialosyllactosylceramide

     Ganglioside GM3 is a monosialoganglioside that demonstrates antiproliferative and proapoptotic effects in tumor cells by modulating cell adhesion, proliferation, and differentiation. Ganglioside GM3 Mixture (sodium salt) Chemical Structure
  50. GC36125 GB-110 GB-110 is a potent, orally active, and nonpeptidic protease activated receptor 2 (PAR2) agonist. GB-110 Chemical Structure
  51. GC38329 GB-110 hydrochloride GB-110 hydrochloride is a potent, orally active, and nonpeptidic protease activated receptor 2 (PAR2) agonist. GB-110 hydrochloride Chemical Structure
  52. GC65439 GB-88 GB-88 is an oral, selective non-peptide antagonist of PAR2, inhibits PAR2 activated Ca2+ release with an IC50 of 2 ?M. GB-88 Chemical Structure
  53. GC73490 GBD-9 GBD-9 is a double-mechanism degrader that efficiently degrades BTK and GSPT1 by recruiting the E3 ligase cereblon (CRBN). GBD-9 Chemical Structure
  54. GC11995 GDC-0834 GDC-0834 is the S-enantiomer of GDC-0834. GDC-0834 Chemical Structure
  55. GC36127 GDC-0834 Racemate Racemic form of GDC-0834 GDC-0834 Racemate Chemical Structure
  56. GC19162 GDC-0853

    RG-7845

     GDC-0853 (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with Kis of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. GDC-0853 has the potential for rheumatoid arthritis and systemic lupus erythematosus research. GDC-0853 Chemical Structure
  57. GC47398 Genistein-d4 An internal standard for the quantification of genistein Genistein-d4 Chemical Structure
  58. GC19167 GLPG0187 An αν?integrin receptor antagonist GLPG0187 Chemical Structure
  59. GC30263 Glucosamine (D-Glucosamine) Glucosamine (D-Glucosamine) (D-Glucosamine (D-Glucosamine)) is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids, is used as a dietary supplement. Glucosamine (D-Glucosamine) Chemical Structure
  60. GC30223 Gly-Arg-Gly-Asp-Ser Gly-Arg-Gly-Asp-Ser is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser Chemical Structure
  61. GC34595 GN44028 A HIF-1 inhibitor GN44028 Chemical Structure
  62. GC13951 GR 144053 trihydrochloride platelet fibrinogen receptor glycoprotein IIb/IIIa (GpIIb/IIIa) antagonist GR 144053 trihydrochloride Chemical Structure
  63. GC33323 GRGDSP GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor. GRGDSP Chemical Structure
  64. GC34265 GRGDSP TFA GRGDSP (TFA) is an integrin inhibitor. GRGDSP TFA Chemical Structure
  65. GC43803 HA-1077 (hydrochloride)

    Fasudil

     Fasudil (HA-1077; AT877) dihydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. HA-1077 (hydrochloride) is also a potent Ca2+ channel antagonist and vasodilator. HA-1077 (hydrochloride) Chemical Structure
  66. GC49882 Hemokinin 1 (human) (trifluoroacetate salt)

    HK-1, TGKASQFFGLM-NH2, Thr-Gly-Lys-Ala-Ser-Gln-Phe-Phe-Gly-Leu-Met-NH2

     A peptide agonist of NK1 receptors Hemokinin 1 (human) (trifluoroacetate salt) Chemical Structure
  67. GC39146 HIF-1 inhibitor-1 An inhibitor of HIF-1 signaling HIF-1 inhibitor-1 Chemical Structure
  68. GC31358 HIF-2α-IN-1 HIF-2α-IN-1 is a HIF-2α inhibitor has an IC50 of less than 500 nM in HIF-2α scintillation proximity assay. HIF-2α-IN-1 Chemical Structure
  69. GC11753 HSDVHK-NH2

    P11

    HSDVHK-NH2 is an inhibitor of the interaction between integrin αvβ3 and vitronectin, with an IC50 value of 1.74 pg/mL (2.414 pM).

     HSDVHK-NH2 Chemical Structure
  70. GC11767 Hydralazine HCl

    1-Hydrazinophthalazine

     Hydralazine HCl is a orally active antihypertensive agent, reduces peripheral resistance directly by relaxing the smooth muscle cell layer in arterial vessel. Hydralazine HCl Chemical Structure
  71. GC64979 I-191 I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonist. I-191 Chemical Structure
  72. GC39194 Ibrutinib D5 Ibrutinib D5 (PCI-32765 D5) is a deuterium labeled Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor. Ibrutinib D5 Chemical Structure
  73. GC60197 Ibrutinib deacryloylpiperidine Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM. Ibrutinib deacryloylpiperidine Chemical Structure
  74. GC36289 Ibrutinib-biotin Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, extracted from patent WO2014059368A1 Compound 1-5, has an IC50 of 0.755-1.02 nM for BTK. Ibrutinib-biotin Chemical Structure
  75. GC32948 IDF-11774 A novel HIF-1 inhibitor IDF-11774 Chemical Structure
  76. GC34301 ILK-IN-2

    CPD 22, Integrin-linked Kinase Inhibitor 1, OSU-T 315

     ILK-IN-2 (OSU-T315 analog) is a ILK inhibitor. ILK-IN-2 Chemical Structure
  77. GC60200 ILK-IN-3 ILK-IN-3 is an integrin linked kinase inhibitor with antitumor activity. ILK-IN-3 Chemical Structure
  78. GC47454 IMS 2186 An anti-choroidal neovascularization agent IMS 2186 Chemical Structure
  79. GC32967 Integrin Antagonists 27 Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist with binding affinity of 18 nM, as s novel anticancer agent. Integrin Antagonists 27 Chemical Structure
  80. GC61613 Integrin modulator 1 Integrin modulator 1 is a potent and selective α4β1 integrin agonist, with an IC50 of 9.8 nM for RGD-binding α4β1. Integrin modulator 1 Chemical Structure
  81. GC12255 IOX4 PHD2 inhibitor IOX4 Chemical Structure
  82. GC32787 iRGD peptide (c(CRGDKGPDC))

    c(CRGDKGPDC)

     iRGD peptide (c(CRGDKGPDC)) is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to av integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. iRGD peptide (c(CRGDKGPDC)) Chemical Structure
  83. GC38801 Irigenin Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells. Irigenin Chemical Structure
  84. GC15379 JNJ-42041935

    HIF-PHD Inhibitor II

     Hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) inhibitor JNJ-42041935 Chemical Structure
  85. GC73427 JNJ-64264681 JNJ-64264681 is a potent, orally active, selective and irreversible covalent BTK inhibitor. JNJ-64264681 Chemical Structure
  86. GC73364 JS25 JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC50 value of 5.8 nM by chelating Tyr551. JS25 Chemical Structure
  87. GC26214 JWH 133

    3-(1,1-dimethylbutyl)-6aR,7,10,10aR-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran

    JWH 133 is a synthetic cannabinoid (CB) that is over 200-fold selective for the peripheral CB2 receptor (Ki = 3.4 nM) over the central CB1 receptor (Ki = 677 nM)

     JWH 133 Chemical Structure
  88. GC73775 KIN-8194 KIN-8194 is an orally active dual inhibitor of HCK and BTK, with IC50 values of 0.915 and <0.495 nM, respectively. KIN-8194 Chemical Structure
  89. GC73414 Larotinib Larotinib is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM. Larotinib Chemical Structure
  90. GC50642 LDV α4β1 (VLA-4) ligand LDV Chemical Structure
  91. GC16190 LDV FITC fluorescent ligand that binds to the α4β1 integrin (VLA-4) LDV FITC Chemical Structure
  92. GC17263 Leukadherin 1 CD11b/CD18 activator Leukadherin 1 Chemical Structure
  93. GC14857 LFM-A13 BTK-specific tyrosine kinase inhibitor LFM-A13 Chemical Structure
  94. GC19222 Lifitegrast

    SAR 1118

     Lifitegrast is an integrin lymphocyte function-associated antigen-1 (LFA-1) antagonist; inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast Chemical Structure
  95. GC90787 Lipid A4

    A branched-chain ionizable cationic lipidoid

     Lipid A4 Chemical Structure
  96. GC13227 LRGILS-NH2 Protease-activated receptor agonist LRGILS-NH2 Chemical Structure
  97. GC47582 Lupulone A beta-acid Lupulone Chemical Structure
  98. GC32724 LW6 (HIF-1α inhibitor)

    Hypoxia-Inducible Factor1α Inhibitor

     LW6 is a hypoxia-inducing factor 1(HIF) inhibitor, which effectively inhibits HIF-1α accumulation by degrading HIF-1α, but does not affect HIF-1A mRNA level during hypoxia. LW6 (HIF-1α inhibitor) Chemical Structure
  99. GC36500 LXW7 LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 Chemical Structure
  100. GC40865 LYG-202 LYG-202 is a synthetic flavonoid with anticancer and anti-angiogenic activities. LYG-202 Chemical Structure
  101. GC32055 MK-0429 (L-000845704)

    L-000845704

     MK-0429 (L-000845704) (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively. MK-0429 (L-000845704) Chemical Structure

Items 101 to 200 of 343 total

per page
  2. 1
  3. 2
  4. 3
  5. 4

Set Descending Direction